Patents by Inventor Lin Zhi

Lin Zhi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10449210
    Abstract: Provided herein are prodrug compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in molecular pathways in the liver. Novel prodrug compounds of acid/alcohol derivatives such as phosphates, phosphonates, phosphonamidates, phosphoramidates, carboxylates, phenolates, and alkoxylates, their preparation and their uses are described. Some of the novel prodrug compounds described herein do not generate a vinyl keto reactive intermediate in the activation process. Another aspect includes the use of prodrugs to treat diseases that benefit from enhanced drug distribution to the liver and like tissues and cells.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: October 22, 2019
    Assignee: LIGAND PHARMACEUTICALS INC.
    Inventor: Lin Zhi
  • Patent number: 10441567
    Abstract: Provided herein are compositions and methods for the treatment of androgen and estrogen receptors mediated conditions. Specifically, a composition that includes an effective amount of a selective estrogen receptor modulator (SERM) and an effective amount of a 5a-reductase inhibitor, or a pharmaceutically acceptable salt, ester or prodrug of the foregoing is provided. Also provided are methods for the treatment of aging related conditions and diseases.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: October 15, 2019
    Assignee: LIGAND PHARMACEUTICALS INCORPORATED
    Inventor: Lin Zhi
  • Patent number: 10435429
    Abstract: Provided herein are 5-fluorouridine monophosphate cyclic triester compounds, their preparation and their uses, such as treating hepatocellular carcinoma and other types of cancer.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: October 8, 2019
    Assignee: Nucorion Pharmaceuticals, Inc.
    Inventor: Lin Zhi
  • Patent number: 10420748
    Abstract: Some embodiments include methods for treating, preventing, reversing, halting, or slowing the progression of cancer, comprising administering to a subject in need thereof an effective amount of one or more chemotherapeutic agents, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, wherein at least one of the chemotherapeutic agents is a cytotoxic granulocyte colony-stimulating factor receptor (GCFR) modulator. Methods are also disclosed for treating, preventing, reversing, halting, or slowing the progression of a hematopoietic disorder, comprising administered a therapeutically effective cytotoxic amount of a GCFR modulator to a subject in need thereof.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: September 24, 2019
    Assignee: LIGAND PHARMACEUTICALS INCORPORATED
    Inventors: Keith B. Marschke, Lin Zhi
  • Publication number: 20190194143
    Abstract: Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia.
    Type: Application
    Filed: August 15, 2017
    Publication date: June 27, 2019
    Inventors: Lin Zhi, Matthew P. Grote, Raja K. Reddy, Wenyu Li, William Craigo
  • Publication number: 20190188016
    Abstract: A method and associated system. In response to a request to deploy a virtual machine, a virtual machine resource usage pattern having attributes matching a subset of attributes in than ordered sequence of attributes is selected from at least one virtual machine resource usage pattern stored in a virtual machine resource usage pattern library, based on an ordering of the attributes in the ordered sequence of attributes, wherein the virtual machine resource usage pattern library stores usage patterns for virtual machines previously deployed. A node on which the virtual machine is to be deployed is selected, based on the selected virtual machine resource usage pattern, and additionally based on either available resources of the plurality of nodes or predicted runtime resource requirements of the virtual machine to be deployed. The virtual machine is configured for being deployed on the selected node. The virtual machine is deployed on the selected node.
    Type: Application
    Filed: February 25, 2019
    Publication date: June 20, 2019
    Inventors: Li Long Chen, Randy A. Rendahl, Xiao Yang Zhu, Lin Zhi Zou
  • Patent number: 10303500
    Abstract: A method and associated system. In response to a request to deploy a virtual machine in a computing environment, a virtual machine resource usage pattern having attributes matching a subset of attributes in than ordered sequence of attributes is selected from at least one virtual machine resource usage pattern stored in a virtual machine resource usage pattern library, based on an ordering of the attributes in the ordered sequence of attributes, wherein the virtual machine resource usage pattern library stores usage patterns for virtual machines previously deployed. A node on which the virtual machine is to be deployed is selected, based on the selected virtual machine resource usage pattern and predicted runtime resource requirements of the virtual machine to be deployed based on historical running data of virtual machines. The virtual machine is configured for being deployed on the selected node. The virtual machine is deployed on the selected node.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: May 28, 2019
    Assignee: International Business Machines Corporation
    Inventors: Li Long Chen, Randy A. Rendahl, Xiao Yang Zhu, Lin Zhi Zou
  • Publication number: 20190099391
    Abstract: Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof.
    Type: Application
    Filed: September 4, 2018
    Publication date: April 4, 2019
    Applicant: LIGAND PHARMACEUTICALS, INC.
    Inventor: Lin ZHI
  • Publication number: 20190100551
    Abstract: Provided herein are 5-fluorouridine monophosphate cyclic triester compounds, their preparation and their uses, such as treating hepatocellular carcinoma and other types of cancer.
    Type: Application
    Filed: September 27, 2018
    Publication date: April 4, 2019
    Inventor: Lin Zhi
  • Publication number: 20190040006
    Abstract: Provided herein are compounds that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.
    Type: Application
    Filed: October 1, 2018
    Publication date: February 7, 2019
    Inventor: Lin Zhi
  • Publication number: 20180369197
    Abstract: Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.
    Type: Application
    Filed: September 10, 2018
    Publication date: December 27, 2018
    Inventors: Lin Zhi, Keith Marschke, Virginia H. Grant, Steven L. Roach, Yixing Shen, Jason C. Pickens, Bijan Pedram, Cornelius Arjan van Oeveren, Lino J. Valdez, Andrew R. Hudson
  • Patent number: 10150788
    Abstract: Provided herein are cyclic phosphorus-containing prodrug compounds, their preparation and their uses, such as treating diseases via modulating molecular targets in the liver.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: December 11, 2018
    Assignee: Ligand Pharmaceuticals, Inc.
    Inventor: Lin Zhi
  • Patent number: 10111859
    Abstract: Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: October 30, 2018
    Assignee: LIGAND PHARMACEUTICALS, INC.
    Inventors: Lin Zhi, Andrew R. Hudson, Keith Marschke, Virginia H. Grant, Steven L. Roach, Yixing Shen, Jason C. Pickens, Bijan Pedram, Cornelius Arjan van Oeveren, Lino J. Valdez
  • Patent number: 10106500
    Abstract: Provided herein are compounds, such as compounds of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: October 23, 2018
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventor: Lin Zhi
  • Publication number: 20180298031
    Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.
    Type: Application
    Filed: June 22, 2018
    Publication date: October 18, 2018
    Inventors: Koc-Kan Ho, David Diller, Jeffrey J. Letourneau, Brian F. McGuinness, Andrew G. Cole, David Rosen, Cornelis A. van Oeveren, Jason C. Pickens, Lin Zhi, Yixing Shen, Bijan Pedram
  • Publication number: 20180291050
    Abstract: Provided herein are cyclic phosphorus-containing prodrug compounds, their preparation and their uses, such as treating diseases via modulating molecular targets in the liver.
    Type: Application
    Filed: June 11, 2018
    Publication date: October 11, 2018
    Inventor: Lin Zhi
  • Patent number: 10076504
    Abstract: Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: September 18, 2018
    Inventor: Lin Zhi
  • Patent number: 10030034
    Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: July 24, 2018
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: Koc-Kan Ho, David Diller, Jeffrey J. Letourneau, Brian F. McGuinness, Andrew G. Cole, David Rosen, Cornelis A. van Oeveren, Jason C. Pickens, Lin Zhi, Yixing Shen, Bijan Pedram
  • Publication number: 20180185333
    Abstract: Some embodiments include methods for treating, preventing, reversing, halting, or slowing the progression of cancer, comprising administering to a subject in need thereof an effective amount of one or more chemotherapeutic agents, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, wherein at least one of the chemotherapeutic agents is a cytotoxic granulocyte colony-stimulating factor receptor (GCFR) modulator. Methods are also disclosed for treating, preventing, reversing, halting, or slowing the progression of a hematopoietic disorder, comprising administered a therapeutically effective cytotoxic amount of a GCFR modulator to a subject in need thereof.
    Type: Application
    Filed: February 28, 2018
    Publication date: July 5, 2018
    Inventors: Keith B. Marschke, Lin Zhi
  • Patent number: 10000522
    Abstract: Some embodiments of the present invention include nucleoside 5?-monophosphate derivative compounds, their preparation and their uses. In some embodiments, such compounds are useful to treat hepatitis C viral infections.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: June 19, 2018
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventor: Lin Zhi